Answers are grounded in this paper and cite their sources.
Analysis reveals the complexity of assessing fetal exposure to maternal drugs, suggesting the need for validated models in development and reproductive toxicology.
While pregnancy exposure data may help in understanding how pregnancy might influence therapeutic outcomes, fetal drug exposure is not a metric of safety. Adequately addressing questions about drug safety during pregnancy will necessarily include a battery of assays based on human relevant models, each sufficiently validated for an aspect of Developmental and Reproductive Toxicology (DART) as its use case.
No takes yet. Share an insight, caveat, or question.
d’Angelo et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: